Otsuka to acquire renal denervation firm ReCor Medical

Share

Otsuka, ReCor MedicalOtsuka Holdings (TYO:4578) said today that it plans to acquire the remaining stake it doesn’t already own in ReCor Medical and the renal denervation device it’s developing to treat hypertension.

Tokyo-based Otsuka led ReCor’s $15 million Series D in April 2015 to back Palo Alto, Calif.- and Amsterdam-based ReCor’s Radiance-HTN study, which will test its Paradise system in patients with high blood pressure in the U.S. and E.U. In May 2016 the duo inked a deal that gave Otsuka exclusive rights to pursue clinical trials, regulatory approval and commercialization of ReCor’s Paradise device in Japan, China, Korea and elsewhere in Asia.

Get the full story on our sister site MassDevice.

DeviceTalks Boston 2018 is Bigger and Better than ever!

textadimage Join us Oct. 8-10 for the 7th annual DeviceTalks Boston, back in the city where it all began.

DeviceTalks offers three days of world-class education, networking, and a technology exhibition featuring the leading companies in the industry.

Early Registration is now open.

Speak Your Mind

*